RAS G12D-mutated NSCLC
specificA change in the nucleotide sequence in a RAS family gene (HRAS, KRAS or NRAS).
13
Centers
13
Active Trials
—
Cancer Funding
Top Centers for RAS G12D-mutated NSCLC(13)
Ranked by research excellence score (trials · grants · publications). Methodology →
| # | Center | Score |
|---|---|---|
| 1 | Dana-Farber Cancer InstituteBoston, MA NCI Comprehensive Active Research Program | 53.8 |
| 2 | Stanford Cancer InstitutePalo Alto, CA NCI Comprehensive Active Research Program | 53.8 |
| 3 | UPMC Hillman Cancer CenterPittsburgh, PA NCI Comprehensive Active Research Program | 53.8 |
| 4 | UC San Diego Moores Cancer CenterLa Jolla, CA NCI Comprehensive Active Research Program | 53.8 |
| 5 | NCI Comprehensive Active Research Program | 53.8 |
| 6 | City of Hope Comprehensive Cancer CenterDuarte, CA NCI Comprehensive Active Research Program | 53.8 |
| 7 | Moffitt Cancer CenterTampa, FL NCI Comprehensive Active Research Program | 53.8 |
| 8 | UC Davis Comprehensive Cancer CenterSacramento, CA NCI Comprehensive Active Research Program | 53.8 |
| 9 | University of Virginia Cancer CenterCharlottesville, VA NCI Comprehensive Active Research Program | 53.8 |
| 10 | The University of Arizona Cancer CenterTucson, AZ NCI Comprehensive Active Research Program | 53.8 |
| 11 | Fred & Pamela Buffett Cancer CenterOmaha, NE NCI Clinical Active Research Program | 53.8 |
| 12 | Boston University Cancer CenterBoston, MA Active Research Program | 53.8 |
| 13 | Active Research Program | 53.8 |
Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →